Assignee
GLENMARK PHARMACEUTICALS SA
CH·45 granted patents·45 pending applications·219 citations·filing 2004–2022
Top patents by PatentIndex Score
90 records- 0196US9493563B2Production of T cell retargeting hetero-dimeric immunoglobulinsGLENMARK PHARMACEUTICALS SA·Filed 2014·Granted Nov 15, 2016·47 cites·3 claims
- 0294US9683053B2Hetero-dimeric immunoglobulinsGLENMARK PHARMACEUTICALS SA·Filed 2014·Granted Jun 20, 2017·38 cites·21 claims
- 0392US9290576B2Antibodies that bind to TL1A and their usesGLENMARK PHARMACEUTICALS SA·Filed 2014·Granted Mar 22, 2016·22 cites·51 claims
- 0487US9855229B2Treatment of respiratory disorders using ROR-gamma inhibitorsGLENMARK PHARMACEUTICALS SA·Filed 2016·Granted Jan 2, 2018·12 cites·5 claims
- 0586US9096545B2Triazolone compounds as mPGES-1 inhibitorsGLENMARK PHARMACEUTICALS SA·Filed 2013·Granted Aug 4, 2015·7 cites·36 claims
- 0685US9439890B2Triazolone compounds as mPGES-1 inhibitorsGLENMARK PHARMACEUTICALS SA·Filed 2015·Granted Sep 13, 2016·4 cites·21 claims
- 0785US7807794B2Anti-α2 integrin antibodies and their usesGLENMARK PHARMACEUTICALS SA·Filed 2006·Granted Oct 5, 2010·11 cites·16 claims
- 0884US7842703B2Substituted benzofused derivatives and their use as vanilloid receptor ligandsGLENMARK PHARMACEUTICALS SA·Filed 2006·Granted Nov 30, 2010·7 cites·40 claims
- 0984US7205323B2Dipeptidyl peptidase IV inhibitors pharmaceutical compositions containing them, and process for their preparationGLENMARK PHARMACEUTICALS SA·Filed 2005·Granted Apr 17, 2007·8 cites·51 claims
- 1082US10821100B2Triazolone compounds as mPGES-1 inhibitorsGLENMARK PHARMACEUTICALS SA·Filed 2019·Granted Nov 3, 2020·1 cites·8 claims
- 1180US9949955B2Triazolone compounds as mPGES-1 inhibitorsGLENMARK PHARMACEUTICALS SA·Filed 2016·Granted Apr 24, 2018·2 cites·12 claims
- 1279US7951814B2Quinazolinedione derivatives as TRPA1 modulatorsGLENMARK PHARMACEUTICALS SA·Filed 2009·Granted May 31, 2011·4 cites·23 claims
- 1379US7943634B2Substituted benzo[4,5]furo[3,2-c]pyridine derivatives as PDE 4 inhibitorsGLENMARK PHARMACEUTICALS SA·Filed 2005·Granted May 17, 2011·3 cites·15 claims
- 1478US7223789B2Heterocyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing themGLENMARK PHARMACEUTICALS SA·Filed 2004·Granted May 29, 2007·13 cites·77 claims
- 1577US10391083B2Triazolone compounds as MPGES-1 inhibitorsGLENMARK PHARMACEUTICALS SA·Filed 2018·Granted Aug 27, 2019·1 cites·14 claims
- 1677US7538128B2Dipeptidyl peptidase IV inhibitors, process for their preparation and compositions containing themGLENMARK PHARMACEUTICALS SA·Filed 2007·Granted May 26, 2009·3 cites·47 claims
- 1777US7393846B2Heterocyclic compounds useful for the treatment of inflammatory and allergic disordersGLENMARK PHARMACEUTICALS SA·Filed 2006·Granted Jul 1, 2008·3 cites·88 claims
- 1877US7384962B2Heterocyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing themGLENMARK PHARMACEUTICALS SA·Filed 2006·Granted Jun 10, 2008·3 cites·25 claims
- 1974US10213558B2Drug delivery deviceGLENMARK PHARMACEUTICALS SA·Filed 2016·Granted Feb 26, 2019·4 cites·20 claims
- 2074US7923465B2Cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparationGLENMARK PHARMACEUTICALS SA·Filed 2006·Granted Apr 12, 2011·3 cites·40 claims
- 2170US7524844B2Dipeptidyl peptidase IV inhibitors, process for their preparation and compositions containing themGLENMARK PHARMACEUTICALS SA·Filed 2007·Granted Apr 28, 2009·1 cites·51 claims
- 2269USD823460SAnal deviceGLENMARK PHARMACEUTICALS SA·Filed 2016·Granted Jul 17, 2018·17 cites·1 claims
- 2369US8987278B2Thienopyrimidinedione derivatives as TRPA1 modulatorsGLENMARK PHARMACEUTICALS SA·Filed 2013·Granted Mar 24, 2015·1 cites·29 claims
- 2469US8349846B2Fused pyrimidine derivatives as TRPV3 modulatorsGLENMARK PHARMACEUTICALS SA·Filed 2009·Granted Jan 8, 2013·2 cites·25 claims
- 2569US2020102403A1T cell retargeting hetero-dimeric immunoglobulinsGLENMARK PHARMACEUTICALS SA·Filed 2019·Application pending·0 cites
- 2665US9682977B2Bicyclic heteroaryl indole analogues useful as ROR gamma modulatorsGLENMARK PHARMACEUTICALS SA·Filed 2014·Granted Jun 20, 2017·1 cites·11 claims
- 2765US9000159B2Fused pyrimidine-dione derivatives as TRPA1 modulatorsGLENMARK PHARMACEUTICALS SA·Filed 2013·Granted Apr 7, 2015·1 cites·16 claims
- 2865US2020024367A1Hetero-Dimeric ImmunoglobulinsGLENMARK PHARMACEUTICALS SA·Filed 2019·Application pending·0 cites
- 2963US10336688B2Carbocyclic compounds as ROR gamma modulatorsGLENMARK PHARMACEUTICALS SA·Filed 2018·Granted Jul 2, 2019·0 cites·10 claims
- 3063US2023000872A1Trpa1 antagonist for the treatment of pain associated to diabetic neuropathic painGLENMARK PHARMACEUTICALS SA·Filed 2022·Application pending·0 cites
- 3162US10988467B2Compounds as ROR gamma modulatorsGLENMARK PHARMACEUTICALS SA·Filed 2019·Granted Apr 27, 2021·0 cites·9 claims
- 3262US2014294824A1Antibodies that bind to ox40 and their usesGLENMARK PHARMACEUTICALS SA·Filed 2014·Application pending·0 cites
- 3361US2020172634A1Expression Constructs and Methods for Expressing Polypeptides in Eukaryotic CellsGLENMARK PHARMACEUTICALS SA·Filed 2019·Application pending·0 cites
- 3461US2020197370A1NANOPARTICULATE FORMULATION COMPRISING AN mPGES-1 INHIBITORGLENMARK PHARMACEUTICALS SA·Filed 2019·Application pending·0 cites
- 3561US2017145115A1Production of T cell retargeting hetero-dimeric immunoglobulinsGLENMARK PHARMACEUTICALS SA·Filed 2016·Application pending·0 cites
- 3660US2009182143A1Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing themGLENMARK PHARMACEUTICALS SA·Filed 2008·Application pending·0 cites
- 3759US10457649B2Polymorphs of a mPGES-1 inhibiting triazolone compoundGLENMARK PHARMACEUTICALS SA·Filed 2018·Granted Oct 29, 2019·0 cites·8 claims
- 3859US2018094077A1Hetero-Dimeric ImmunoglobulinsGLENMARK PHARMACEUTICALS SA·Filed 2017·Application pending·0 cites
- 3959US2020010568A1Purification of hetero-dimeric immunoglobulinsGLENMARK PHARMACEUTICALS SA·Filed 2019·Application pending·0 cites
- 4058US2017260280A1Antibodies that Bind to OX40 and Their UsesGLENMARK PHARMACEUTICALS SA·Filed 2016·Application pending·0 cites
- 4158US2018112011A1T cell retargeting hetero-dimeric immunoglobulinsGLENMARK PHARMACEUTICALS SA·Filed 2015·Application pending·0 cites
- 4257US2020079863A1Antibodies that bind to tl1a and their usesGLENMARK PHARMACEUTICALS SA·Filed 2019·Application pending·0 cites
- 4356US2009281146A1Process for the preparation of n-(3,5-dichloropyrid-4-yl)-4-difluoromethoxy-8-methanesulfonamido-dibenzo[b,d]furan-1-carboxamideGLENMARK PHARMACEUTICALS SA·Filed 2009·Application pending·0 cites
- 4456US2015056655A1Expression constructs and methods for expressing polypeptides in eukaryotic cellsGLENMARK PHARMACEUTICALS SA·Filed 2014·Application pending·0 cites
- 4555US2019056396A1Expression constructs and methods for selecting host cells expressing polypeptidesGLENMARK PHARMACEUTICALS SA·Filed 2018·Application pending·0 cites
- 4654US10112914B2Polymorphs of a mPGES-1 inhibiting triazolone compoundGLENMARK PHARMACEUTICALS SA·Filed 2016·Granted Oct 30, 2018·0 cites·10 claims
- 4754US9073955B22-amino-4-arylthiazole compounds as TRPA1 antagonistsGLENMARK PHARMACEUTICALS SA·Filed 2013·Granted Jul 7, 2015·0 cites·6 claims
- 4854US8889862B22-amino-4-arylthiazole compounds as TRPA1 antagonistsGLENMARK PHARMACEUTICALS SA·Filed 2013·Granted Nov 18, 2014·0 cites·6 claims
- 4954US2015183885A1Anti-trka antibodies with enhanced inhibitory properties and derivatives thereofGLENMARK PHARMACEUTICALS SA·Filed 2014·Application pending·0 cites
- 5054US2014341892A1Anti-alpha2 integrin antibodies and their usesGLENMARK PHARMACEUTICALS SA·Filed 2014·Application pending·0 cites
Showing the top 50 of 90 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →